# Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Source: https://onco.cc/trials/nct06280495/  
OnCo record `nct06280495` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of fOLFOX (5-FU, leucovorin, oxaliplatin), fluorouracil (5-FU), serplulimab and bevacizumab (glioblastoma use) in colorectal cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients is a phase 2/3, randomised interventional study registered as NCT06280495 by Sun Yat-sen University, with a registry enrolment figure of 156 participants, started 2024-02-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Oxaliplatin; Fluorouracil; Serplulimab; Bevacizumab. Conditions listed: Colorectal Cancer; Liver Metastases. Primary outcome: 3-year Progression-Free Survival Rate. Colorectal eligibility wording from the registry: "* Histologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06280495
- Phase: 2/3
- Setting: Neoadjuvant Combination of Serplulimab and Bevacizumab With FOLFOX Versus FOLFOX Alone for Resectable Liver Metastases in RAS/BRAF Wild-Type, pMMR/MSS Colorectal Cancer Patients
- Sponsor: Sun Yat-sen University
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT06280495: https://clinicaltrials.gov/study/NCT06280495

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06280495.json